


LSP Life Sciences Fund

LSP
Life Sciences Partners

Monthly Report March 2014

NAV per Share

€ 156.85



NAV of Fund 62,496,225

Number of Shares 398,432

Valuation Date 31/03/2014

Inception date: 27/04/2011

Currency: Euro

Domicile: The Netherlands

Legal Structure: Dutch NV with variable capital

Listing: Euronext Amsterdam

Euronext code: LSP

ISIN Code: NL0009756394

Bloomberg: LSP NA

Investment strategy

The Fund's primary investment objective is to achieve capital appreciation by investing in a diversified, yet concentrated portfolio of publicly listed life sciences companies (including biopharmaceutical-, specialist pharmaceutical-, medical device-, drug delivery-, vaccine- and diagnostic companies). The majority of the Fund's portfolio will consist of European companies listed on one of the (main) European stock exchanges, with a market capitalization of below € 1 billion at the time of investment.




Manager's comments

In the month of March we saw a negative performance in the general biotech markets. Such following a sell-off in Gilead Sciences, one of the strongest recent performers in large-cap US biotech, triggered by a US senator questioning the price of the company's new HCV treatment. As a result, during the month of March, the NASDAQ Biotech Index or NBI, an index in which only US biotech stocks are represented including the largest cap biotechs, lost some 11% of its value. The portfolio of the LSP Life sciences Fund also lost some value during the month (3%) due to the general sentiment turning somewhat, however – importantly - none of it due to portfolio company specific negative news. In fact, during this month, MorphoSys announced favourable Phase II data for one of its clinical programs partnered with Johnson&Johnson and Innate Pharma announced a positive update of its most important clinical program which is partnered with BMS. Given the highly concentrated nature of the fund's portfolio, its performance is driven by company specific catalysts, such as clinical trial data, partnering news, corporate news, technology updates etc. The current portfolio contains a number of such catalysts to play out in the coming weeks and months. The fund closed the quarter with an increase of its NAV of +17%.

Top-5 performers

1. InterMune	+ 10.1%
2. Enanta Pharma.	+ 8.9%
3. Sphere Medical	+ 0.9%
4. NeoStem	+ 0.7%
5. MorphoSys	+ 0.1%

Portfolio breakdown



Important information

LSP Advisory B.V. (as Fund Manager) and the LSP Life Sciences Fund N.V. (the Fund) have a license and are registered pursuant to the Dutch Act on Financial Supervision and are supervised by the Stichting Autoriteit Financiële Markten (Dutch Authority for the Financial Markets) and De Nederlandsche Bank N.V. (the Dutch Central Bank). This presentation is solely for information purposes and is not intended as advice in any way. The Fund Manager and the Fund cannot be held liable or responsible for the content of this presentation. Potential investors are advised to contact their investment- and fiscal advisor prior to taking an investment decision. There are risks involved in the investment. The value of the investment can fluctuate. Results achieved in the past offer no guarantee for the future. A Key Investor Information Document is also available for this product with information about the product, the costs and the risks involved. Read it before you invest in the product. The prospectus and the Key Investor Information Document of the LSP Life Sciences Fund can be downloaded via www.lsplifesciencesfund.com.

LSP Life Sciences Fund

Top-10 portfolio positions

Company	Stage	Subsector	Marketcap	%
AcelRX	Late	Medical Device	Small	10.8%
Lombard Medical	Late	Medical Device	Micro	7.9%
InterMune	Market	Therapeutics	Mid	7.8%
Ablynx	Early	Therapeutics	Small	7.7%
Neurocrine Biosciences	Late	Therapeutics	Small	7.3%
Enanta Pharmaceuticals	Late	Therapeutics	Small	6.3%
Galapagos	Late	Therapeutics	Small	6.1%
Genmab	Market	Therapeutics	Mid	5.9%
EVOTEC	Market	Therapeutics	Small	5.8%
Synergy Pharmaceuticals	Late	Therapeutics	Small	5.5%